Naporafenibum is under clinical development by Erasca and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Naporafenibum’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naporafenibum overview

Naporafenibum (LXH-254) is under development for the treatment of advanced solid tumors including metastatic melanoma, metastatic colorectal cancer, colon cancer, non small cell lung cancer. The drug candidate is administered orally. It acts by targeting pan RAF kinase. It is a new molecular entity (NME).

Erasca overview

Erasca is an oncology drug development company that uses its artificial intelligence drug discovery platform to treat and cure cancer. The company is headquartered in San Diego, California, the US.

For a complete picture of Naporafenibum’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.